Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Correvio Pharma Corp. CORV

Healthcare Drug Manufacturers - Major
Correvio Pharma Corp is specialty pharmaceutical company. It offers patients and healthcare providers therapeutic solutions for acute medical conditions to improve health and quality of life. Its products are Aggrastat, Esmocard, Brinavess, Xydalba, Zevtera/Mabelio, and others. It offers solutions on Acute Bacterial Skin and Skin Structure Infections, Acute Coronary Syndromes, Atrial... see more

Recent & Breaking News (NDAQ:CORV)

Correvio to Present at Upcoming Investor Conferences

PR Newswire March 7, 2019

Correvio To Report Fourth Quarter And Full Year 2018 Financial Results On March 13, 2019

Canada NewsWire March 6, 2019

Correvio to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

Canada NewsWire February 21, 2019

Correvio Announces Presentation Of Brinavess Data At Belgian Society Of Cardiology 2019 Annual Congress

Canada NewsWire February 7, 2019

Correvio Provides Update On At The Market Offering

Canada NewsWire January 17, 2019

Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes

Canada NewsWire January 2, 2019

Correvio to Present at the 30th Annual Piper Jaffray Healthcare Conference

Canada NewsWire November 20, 2018

Correvio Reports Third Quarter 2018 Financial Results

Canada NewsWire November 6, 2018

Correvio to Report Third Quarter 2018 Financial Results on November 6, 2018

Canada NewsWire October 30, 2018

Correvio Announces Brinavess Eligibility for Patent Extension

PR Newswire October 29, 2018

Correvio Announces Intention to Re-File Brinavess® NDA in Second Quarter 2019

PR Newswire October 23, 2018

Correvio to Participate In Upcoming Investor Conferences

Canada NewsWire September 20, 2018

Correvio Reports Preliminary Data Collected from >2,000 Brinavess® Treatment Episodes in EU Post-Authorization Safety Study

Canada NewsWire September 5, 2018

Correvio Highlights Completion of SteadyMed Acquisition by United Therapeutics

Canada NewsWire September 4, 2018

Correvio to Participate in Upcoming Investor Conferences

Canada NewsWire August 28, 2018

Correvio Announces EU Survey Data Demonstrating Brinavess Successfully Avoided Hospitalization in 85% of Patients

Canada NewsWire August 16, 2018

Correvio Reports Second Quarter 2018 Financial Results

PR Newswire August 14, 2018

Correvio Announces Brinavess® Selected as Potentially Eligible for Priority Review in China

Canada NewsWire August 14, 2018

Correvio To Report Second Quarter 2018 Financial Results On August 14, 2018

Canada NewsWire August 7, 2018

Correvio to present at the Canaccord Genuity 38th Annual Growth Conference

Canada NewsWire August 1, 2018